A Maintenance Study Evaluating the Long Term Safety of XL999 Administered Intravenously to Subjects With Advanced Malignancies Previously Enrolled in Other XL999 Studies.
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2010
At a glance
- Drugs XL 999 (Primary)
- Indications Cancer
- Focus Therapeutic Use
- 23 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2010 Last checked against ClinicalTrials.gov record.
- 16 Dec 2009 New trial record